Drug delivery technology is the critical enabling layer that determines whether biologic therapies can reach their cellular targets safely and effectively. Lipid nanoparticles — proven at unprecedented scale through mRNA COVID-19 vaccines — are being adapted for mRNA therapy delivery to liver, lung, and other tissues. GalNAc conjugates — Alnylam's hepatocyte-targeting delivery technology — enable subcutaneous self-administration of RNAi therapeutics with remarkable dosing convenience. AAV vectors for gene therapy face manufacturing scale challenges and immunogenicity constraints. The competition to develop better delivery systems is as commercially important as the development of the therapeutic payloads they carry.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Lipid Nanoparticle Technology
• GalNAc Delivery for RNAi
• AAV Vector Engineering
• Nanoparticle Drug Delivery
• Subcutaneous vs. IV Delivery
• Tissue-Targeting Strategies
• Manufacturing of Delivery Systems
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Technology Landscape Overview
3. Lipid Nanoparticle Technology
4. GalNAc Delivery for RNAi
5. AAV Vector Engineering
6. Nanoparticle Drug Delivery
7. Subcutaneous vs. IV Delivery
8. Tissue-Targeting Strategies
9. Manufacturing of Delivery Systems
10. Competitive Landscape
11. Competitive Landscape
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Technology Overview and Key Data 2025
Table 2. Lipid Nanoparticle Technology
Table 3. GalNAc Delivery for RNAi
Table 4. AAV Vector Engineering
Table 5. Nanoparticle Drug Delivery
Table 6. Subcutaneous vs. IV Delivery
Table 7. Tissue-Targeting Strategies
Table 8. Manufacturing of Delivery Systems
Table 9. Competitive Landscape
Table 10. Leading Companies — Technology Investment and Strategy 2025
Table 11. M&A and Partnership Activity 2023-2025
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
Spark Therapeutics
BioMarin
Sarepta
bluebird bio
Ultragenyx
Novartis Gene Therapies
Regenxbio
